TSC1 clinical trials at UCSF
1 research study open to eligible people
TSC1 is a study at UCSF for patients with certain types of cancer. The trial is testing nab-sirolimus for adult and adolescent patients with malignant solid tumors. You may be eligible if you have specific changes in your TSC1/TSC2 genes and have already received standard treatment.
Showing trials for
Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)
open to eligible people ages 12 years and up
A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes
San Francisco, California and other locations
Our lead scientists for TSC1 research studies include Brian Schulte, MD.